Skip to content

Clinical trials

Observational Antiphospholipid Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Antiphospholipid Syndrome Phase: Observational Clear all

47 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20052
20062
20091
20101
20112
20132
20156
20171
20182
20194
20203
20211
20226
20242
20256
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed21
Recruiting13
Unknown status6
Not yet recruiting5
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris4
Central Hospital, Nancy, France4
Centre Hospitalier Universitaire de Nīmes3
Cardioangiologisches Centrum Bethanien2
Hospices Civils de Lyon2
Hospital for Special Surgery, New York2
Saint Thomas Hospital, Panama2
University Hospital, Strasbourg, France2
University of North Carolina, Chapel Hill2
Yale University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Antiphospholipid Syndrome47
Lupus Erythematosus, Systemic8
Arthritis, Rheumatoid5
Scleroderma, Systemic4
Thrombophilia4
Thrombosis4
COVID-193
Myositis3
Sjogren's Syndrome3
Spondylitis, Ankylosing3

Trials

Showing 51 to 47 of 47. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.